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It is now clear that are two histological types (Type-1 and Type-2) of autoimmune
pancreatitis (AIP). The histological pattern of Type-1 AIP, or traditional AIP, is called
lymphoplasmacytic sclerosing pancreatitis (LPSP). The histological pattern of Type-2 AIP is
characterized by neutrophilic infiltration in the epithelium of the pancreatic duct. In general,
Type-2 AIP patients are younger, may not have a male preponderance, and rarely show
elevation of serum IgG4 compared with Type-1 AIP patients. Unlike Type-1 AIP patients,
Type-2 AIP patients rarely have associated sclerosing diseases, but they are more likely to
have acute pancreatitis and ulcerative colitis. Although Type-2 AIP is sometimes observed
in the USA and Europe, most AIP cases in Japan and Korea are Type-1. The international
consensus diagnostic criteria for AIP comprise 5 cardinal features, and combinations of
one or more of these features provide the basis for diagnoses of both Type-1 and Type-2
AIP. Due to the fact that steroid therapy is clinically, morphologically, and serologically
effective in AIP patients, it is the standard therapy for AIP. The indications for steroid
therapy in AIP include symptoms such as obstructive jaundice and the presence of
symptomatic extrapancreatic lesions. Oral prednisolone (0.6mg/kg/day) is administered
for 2–4 weeks and gradually tapered to a maintenance dose of 2.5–5 mg/day over a period
of 2–3 months. Maintenance therapy by low-dose prednisolone is usually performed for
1–3 years to prevent relapse of AIP.
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INTRODUCTION
Autoimmune pancreatitis (AIP) is a rare disease that has recently
emerged as a peculiar type of pancreatitis with a presumed
autoimmune etiology. In 1991, Kawaguchi et al. reported two
cases of an unusual inflammatory disease involving the pancreas
and biliary tract that were resected on suspicion of pancreatic can-
cer and, based on the peculiar findings of dense infiltration of
lymphocytes and plasma cells with marked fibrosis, described the
condition as lymphoplasmacytic sclerosing pancreatitis (LPSP)
(Kawaguchi et al., 1991). In 1995, Yoshida et al. first proposed
the concept of AIP, and they summarized the clinical features as
follows: increased serum γ-globulin or IgG levels and the pres-
ence of autoantibodies; diffuse irregular narrowing of the main
pancreatic duct and enlargement of the pancreas; occasional asso-
ciation with stenosis of the lower bile duct and other autoimmune
diseases; mild symptoms, usually without acute attacks of pancre-
atitis; effectiveness of steroid therapy; and histological finding of
LPSP (Yoshida et al., 1995). In 2001, serum IgG4 levels were found
to be frequently elevated in AIP patients (Hamano et al., 2001).
Since, AIP is frequently associated with various extrapancreatic
sclerosing lesions with the same peculiar histological findings as
seen in the pancreas, AIP is currently considered to represent a
pancreatic lesion of an IgG4-related systemic disease (Kamisawa
et al., 2003a,b, 2010c).
Using retrospective, histological examination of pancreases
resected on suspicion of pancreatic cancer from patients with
mass-forming chronic pancreatitis, American and European
pathologists have described another unique histological pattern,
called idiopathic duct-centric pancreatitis (IDCP) (Notohara
et al., 2003), or AIP with granulocytic epithelial lesion (GEL)
(Zamboni et al., 2004). Recently, LPSP has been called Type-1
AIP, and IDCP has been called Type-2 AIP (Sah et al., 2010). This
review focuses on the differences between Type-1 and Type-2 AIP,
the recently proposed international consensus diagnostic criteria
for AIP (Shimosegawa et al., 2011), and the Japanese standard
therapeutic regimen for AIP.
TWO SUBTYPES OF AUTOIMMUNE PANCREATITIS:
TYPE-1 AND TYPE-2
The pathological features of Type-1 and Type-2 AIP differ clearly.
LPSP of Type-1 AIP consists of dense infiltration of lymphocytes
and IgG4-positive plasma cells and fibrosis that involves pancre-
atic lobules, ducts and peripancreatic adipose tissue (Kawaguchi
et al., 1991; Kamisawa et al., 2003a,b, 2010c). Storiform fibro-
sis, a swirling pattern of fibrosis mixed with inflammatory
cells, and obliterative phlebitis are characteristic and diagnos-
tic (Figure 1). Eosinophils are often present, but neutrophils are
absent. Neutrophilic infiltration within the lumen and epithelium
of interlobular ducts is a characteristic feature of IDCP of Type-
2 AIP (Notohara et al., 2003; Zamboni et al., 2004). Infiltration
of IgG4-positive plasma cells is rare (Kamisawa et al., 2010a;
Shimosegawa et al., 2011).
Since no apparent serological markers have yet been found
for Type-2 AIP, histological examination is necessary to diagnose
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FIGURE 1 | Histological feature of the pancreas of Type-1 AIP.
Type-2 AIP, and thus its clinical diagnosis is difficult. Although
the clinical features of Type-2 AIP are not as well-known as those
of Type-1 AIP, Type-2 AIP patients show quite different clinical
profiles from Type-1 AIP patients. Age at diagnosis of Type-2
AIP is more than a decade younger, and Type-2 AIP does not
show a male preponderance. Type-2 AIP patients are less likely
to show elevated serum IgG4 levels and IgG4-related extrapan-
creatic sclerosing lesions such as proximal sclerosing cholangitis,
sclerosing sialadenitis, and retroperitoneal fibrosis. Type-2 AIP
is more likely associated with acute pancreatitis and inflamma-
tory bowel disease. Type-2 AIP tends to have focal features and
is more commonly surgically resected due to the diagnostic diffi-
culty. Although endocrine and exocrine functions of the pancreas
are frequently impaired in Type-1 AIP, the functions in Type-
2 AIP are unknown. Both Type-1 and Type-2 AIP respond well
to steroids, but relapse of Type-2 AIP is rarely seen, whereas
Type-1 sometimes relapses (Notohara et al., 2003; Zamboni et al.,
2004; Kamisawa et al., 2010a; Sah et al., 2010; Shimosegawa et al.,
2011). The prevalence of Type-1 and Type-2 AIP differ around the
world. In Japan and Korea, most AIP cases are Type-1, and Type-
2 AIP is quite rare (Kamisawa et al., 2011). However, Type-2 AIP
may comprise about 20–40% of AIP cases in the United States
of America and Europe (Notohara et al., 2003; Zamboni et al.,
2004; Park et al., 2009). Whether these differences are induced
by regional or racial elements or low recognition of the disease
remains unclear.
INTERNATIONAL CONSENSUS DIAGNOSTIC CRITERIA
The international consensus diagnostic criteria for AIP
(Shimosegawa et al., 2011) were developed to be applicable
worldwide, diagnose AIP safely, avoid misdiagnosis of pancreatic
cancer as AIP, and diagnose AIP in acute presentation. Criteria
for Type-1 and Type-2 AIP were developed separately. The
diagnosis of AIP is made by a combination of one or more of
five cardinal features: (1) imaging features of the pancreatic
parenchyma and pancreatic duct; (2) serology; (3) other organ
involvement (OOI); (4) histology of the pancreas; and (5) an
optional criterion of response to steroid therapy. Each feature
has been categorized as level 1 and 2 findings depending on the
diagnostic reliability. The diagnoses of Type-1 and Type-2 AIP
can be definitive or probable, and in some cases, the distinction
between the subtypes may not be possible (AIP-not otherwise
specified). Diagnosis of sero-negative Type-1 AIP is sometimes
difficult.
Cross-sectional pancreatic imaging on CT or MRI is consid-
ered as the first essential clue, and the findings have been divided
into typical diffuse enlargement and indeterminate images of seg-
mental or focal enlargement of the pancreas. For the criterion
related to the pancreatic duct on endoscopic retrograde pancre-
atography (ERP), level 1 is long or multiple narrowings without
marked upstream dilatation, and level 2 is segmental or focal nar-
rowing without marked upstream dilatation. For the serological
criterion for Type-1 AIP, level 1 is marked elevation of serum IgG4
levels (more than double upper limit of normal value), and level 2
is mild elevation of serum IgG4 levels. For the criterion of OOI for
Type-1 AIP, level 1 is either histological findings in extrapancre-
atic organs (any three of the four features) or typical radiological
evidence (proximal bile duct stricture or retroperitoneal fibrosis),
and level 2 is histological findings or physical or radiological evi-
dence (symmetrically enlarged salivary/lacrimal glands or renal
involvement). For the histological criterion for Type-1 AIP, level 1
is LPSP with more than three features on core biopsy or resected
specimens, and level 2 is any two features on core biopsy speci-
mens. A diagnostic steroid trial is an optional criterion. Response
to steroid therapy is defined as rapid (within 2 weeks), radi-
ologically demonstrable resolution or marked improvement in
pancreatic or extrapancreatic manifestations. However, a steroid
trial should be used only after a negative work-up for cancer,
including endoscopic ultrasound-guided fine needle aspiration
(Table 1). For the criteria for Type-2 AIP, there is no serological
criterion; the criterion of OOI is only level 2 (clinically diag-
nosed inflammatory bowel disease); and the histological criterion
is granulocytic infiltration and absent or scant IgG4-positive cells.
Definitive Type-1 can be diagnosed only by histological exam-
ination of resected pancreas or core biopsy specimens showing
LPSP. To diagnose definitive Type-1, in cases with diffuse imaging
findings, any additional non-ductal cardinal criterion is neces-
sary. In cases with segmental or focal imaging, two or more from
any level 1 and ductal level 2 cardinal criteria are necessary. To
make the diagnosis in association with response to steroid ther-
apy, one non-ductal level 1 or ductal level 1 with any non-ductal
level 2 cardinal criterion is necessary. Response to steroid with
one non-ductal level 2 cardinal criterion is diagnosed as probable
Type-1 AIP (Table 2).
To diagnose definite Type-2 AIP, histologically confirmed
IDCP or clinical inflammatory bowel disease with level 2 histol-
ogy and response to steroid is necessary.
JAPANESE STANDARD STEROID TREATMENT FOR AIP
Steroid therapy is clinically, morphologically, and serologically
effective in AIP patients, and as a result, it has become the stan-
dard current therapy for AIP. From the international survey of
AIP (Kamisawa et al., 2011), steroid therapy is standard for AIP
Frontiers in Physiology | Gastrointestinal Sciences October 2012 | Volume 3 | Article 374 | 2
Kamisawa et al. Autoimmune pancreatitis
Table 1 | Level 1 and level 2 criteria for Type-1 AIP.
Criterion Level 1 Level 2
Parenchymal imaging Typical: diffuse enlargement with delayed enhancement
(sometimes associated with rim-like enhancement)
Indeterminate (including atypical): segmental/focal
enlargement with delayed enhancement
Ductal imaging (ERP) Long (>1/3 length of the main pancreatic duct) or
multiple strictures without marked upstream dilatation
Segmental/focal narrowing without marked upstream
dilatation (duct size, <5mm)
Serology IgG4, >2x_ upper limit of normal value IgG4, 1–2x_upper limit of normal value
Other organ
involvement (OOI)
a or b
a. Histology of extrapancreatic organs
Any three of the following:
(1) Marked lymphoplasmacytic infiltration with fibrosis
and without granulocytic infiltration
(2) Storiform fibrosis granulocytic infiltration
(3) Obliterative phlebitis
(4) Abundant (>10 cells/HPF) IgG4-positive cells
b. Typical radiological evidence
At least one of the following:
(1) Segmental/multiple proximal (hilar/intrahepatic) or
proximal and distal bile duct stricture
(2) Retroperitoneal fibrosis
a or b
a. Histology of extrapancreatic organs including endoscopic
biopsy of bile duct
Both of the following:
(1) Marked lymphoplasmacytic infiltration with fibrosis
without granulocytic infiltration
(2) Abundant (>10 cells/HPF) IgG4-positive cells
b. Physical or radiological evidence
At least one of the following:
(1) Symmetrically enlarged salivary/lacrimal glands
(2) Radiological evidence of renal involvement described in
association with AIP
Histology of the
pancreas
LPSP (core biopsy/resection)
At least 3 of the following:
(1) Periductal lymphoplasmacytic infiltrate without
granulocytic infiltration
(2) Obliterative phlebitis
(3) Storiform fibrosis
(4) Abundant (>10 cells/HPF) IgG4-positive cells
LPSP (core biopsy)
Any 2 of the following:
(1) Periductal lymphoplasmacytic infiltrate without
granulocytic infiltration
(2) Obliterative phlebitis
(3) Storiform fibrosism
(4) Abundant (>10 cells/HPF) IgG4-positive cells
Diagnostic steroid trial. Response to steroid (Rt) Rapid (e2 wk) radiologically demonstrable resolution or marked improvement in pancreatic/extrapancreatic
manifestations.
Table 2 | Diagnosis of definitive and probable Type-1 AIP using international consensus diagnostic criteria.
Diagnosis Primary basis for diagnosis Imaging evidence Collateral evidence
Definitive Type-1 AIP Histology Typical/indeterminate Histologically confirmed LPSP (level 1 H)
Imaging Typical Any non-D level 1/level 2
Indeterminate Two or more from level 1 (+level 2 D∗)
Response to steroid Indeterminate Level 1 S/OOI + Rt or level 1 D + level 2 S/OOI/H + Rt
Probable Type-1 AIP Indeterminate Level 2 S/OOI/H + Rt
∗Level 2 D is counted as level 1 in this setting.
in all countries. According to the Japanese consensus guideline for
the management of AIP (Kamisawa et al., 2010b), the indications
for steroid therapy in AIP include symptoms such as obstruc-
tive jaundice and the presence of symptomatic extrapancreatic
lesions. Before steroid therapy, obstructive jaundice should be
controlled by biliary drainage and blood glucose levels should be
regulated, usually by administration of insulin in diabetes melli-
tus patients. The initial recommended dose of oral prednisolone
for induction of remission is 0.6mg/kg/day, administered for
2–4 weeks. Biochemical and serological blood tests, such as liver
enzyme and IgG4 levels, as well as imaging tests, such as CT,
MRCP, and ERCP, are performed periodically after the start of
steroid therapy. Pancreatic size usually normalizes within a few
weeks, and biliary drainage becomes unnecessary within about
1 month. Rapid response to steroids is reassuring and confirms
the diagnosis of AIP. If steroid effectiveness is reduced, the patient
should be re-evaluated on suspicion of pancreatic cancer. The
dose is gradually tapered to a maintenance dose of 2.5–5mg/day
over a period of 2–3 months.
Remission is defined as, the disappearance of clinical symp-
toms and resolution of the pancreatic and/or extrapancre-
atic manifestations on imaging studies. In the Japanese mul-
ticenter survey of steroid therapy for AIP (Kamisawa et al.,
2009), the remission rate of AIP patients treated with steroid
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was 98% (451/459). At remission, the enlarged pancreas returned
to near-normal size in 239 (80%) of 300 patients and became
atrophic in 58 patients (20%). Elevated serum IgG4 levels
decreased in all patients after the start of steroid therapy, but
they failed to normalize in 115 (63%) of 182 patients. HbA1c and
impaired pancreatic exocrine function improved and normalized
in half of them.
Relapse of AIP is defined as reappearance of symptoms accom-
panied by the reappearance of pancreatic and/or extrapancreatic,
including bile duct, salivary gland, and retroperitoneal abnor-
malities on imaging and/or elevation of serum IgG4 levels. In a
multicenter survey (Kamisawa et al., 2009), the relapse rate of
AIP patients treated with steroid was 24% (110/451). Relapse
occurred in the pancreas (n = 57, 52%), bile duct (n = 37, 34%),
and extrapancreatic lesions (n = 19). Maintenance steroid ther-
apy was given after remission in 377 (82%) of 459 patients
treated with steroid. The maintenance oral prednisolone dose
was 10mg/day (n = 27, 7%), 7.5mg/day (n = 13, 3%), 5mg/day
(n = 238, 63%), 2.5mg/day (n = 78, 21%), and others. The
relapse rate with maintenance therapy was 23% (63/273), which
was significantly lower than that of patients who stopped main-
tenance therapy (34%, 35/104; p < 0.05). In the USA and UK,
where no maintenance therapy was given, relapse rates of patients
treated with steroid were reportedly 38% (Sandanayake et al.,
2009) and 53% (Ghazale et al., 2008). Whether maintenance ther-
apy benefits AIP patients remains unconfirmed, but given these
findings, maintenance therapy with low dose prednisolone (2.5–
5mg/day) was recommended to prevent relapse (Kamisawa et al.,
2009, 2010b). In a multicenter study (Kamisawa et al., 2009),
of the 377 patients who underwent maintenance therapy, main-
tenance therapy was stopped in 104 (28%) in whom complete
radiological and serological improvement was achieved. As to the
period from the start of steroid therapy to relapse, 32% (32/99)
relapsed within 6 months, 56% (55/99) relapsed within 1 year,
76% (75/99) relapsed within 2 years, and 92% (91/99) relapsed
within 3 years after starting medication. Maintenance therapy
should be stopped within 1–3 years in cases with radiological
and serological improvement to prevent steroid-related compli-
cations such as osteoporosis, diabetes, and infection (Kamisawa
et al., 2009, 2010b) (Figure 2).
For relapsed AIP, re-administration or dose-up of steroid
was effective. In the USA and UK, immunomodulatory drugs
such as azathioprine were used in addition to re-administered
steroid for relapsed patients, and remission was again achieved
FIGURE 2 | Regimen of Japanese standard steroid treatment for AIP.
and maintained on long-term azathioprine (Ghazale et al., 2008;
Sandanayake et al., 2009).
It has been reported that the predictors for relapse are the
presence of proximal bile duct stenosis and elevated serum IgG4
levels (Ghazale et al., 2008; Kamisawa et al., 2009; Sah et al., 2010;
Takuma et al., 2011). Pancreatic stones are formed in relapsing
AIP patients, which might be induced by pancreatic juice stasis
from intensified incomplete obstruction of the pancreatic duct
system (Takuma et al., 2011; Maruyama et al., 2012). Since, AIP
might transform into ordinary chronic pancreatitis after several
relapses, relapses of AIP should be avoided as much as possible.
It is necessary to verify the validity of the Japanese regimen
of steroid therapy for AIP: the necessity, drugs, and duration of
maintenance therapy need to be clarified by prospective studies.
CONCLUSIONS
Type-1 andType-2 AIP are clinicopathologically different entities.
International consensus diagnostic criteria can be used to diag-
nose Type-1 and Type-2 AIP. Steroid therapy is standard therapy
for AIP, but the regimen should be evaluated in prospective trials.
ACKNOWLEDGMENTS
This work was supported in part by the Research Committee
of Intractable Pancreatic Diseases (Principal investigator: Tooru
Shimosegawa) provided by the Ministry of Health, Labour, and
Welfare of Japan.
REFERENCES
Ghazale, A., Chari, S. T., Zhang, L.,
Smyrk, T. C., Takahashi, N., Levy,
M. J., et al. (2008). Immunoglobulin
G4-associated cholangitis: clinical
profile and response to therapy.
Gastroenterology 134, 706–715.
Hamano, H., Kawa, S., Horiuchi, A.,
Unno, H., Furuya, N., Akamatsu,
T., et al. (2001). High serum IgG4
concentrations in patients with scle-
rosing pancreatitis. N. Engl. J. Med.
344, 732–738.
Kamisawa, T., Chari, S. T., Giday, S.
A., Kim, M. H., Chung, J. B., Lee,
K. T., et al. (2011). Clinical pro-
file of autoimmune pancreatitis and
its histological subtypes: an interna-
tional multicenter survey. Pancreas
40, 352–358.
Kamisawa, T., Funata, N., Hayashi,
Y., Eishi, Y., Koike, M., Tsuruta,
K., et al. (2003a). A new
clinicopathological entity of
IgG4-related autoimmune disease.
J. Gastroenterol. 38, 982–984.
Kamisawa, T., Funata, N., Hayashi,
Y., Tsuruta, K., Okamoto, A.,
Amemiya, K., et al. (2003b). Close
relationship between autoim-
mune pancreatitis and multifocal
fibrosclerosis. Gut 52, 683–687.
Kamisawa, T., Notohara, K., and
Shimosegawa, T. (2010a). Two
clinicopathologic subtypes of
autoimmune pancreatitis: LPSP and
IDCP. Gastroenterology 139, 22–25.
Kamisawa, T., Okazaki, K., Kawa,
S., Shimosegawa, T., Tanaka M.,
Research Committee for Intractable
Pancreatic Disease, and Japan
Pancreas Society. (2010b). Japanese
consensus guidelines for manage-
ment of autoimmune pancreatitis:
III. Treatment and prognosis of AIP.
J. Gastroenterol. 45, 471–477.
Kamisawa, T., Takuma, K., Egawa,
N., Tsuruta, K., and Sasaki, T.
(2010c). Autoimmune pancreatitis
and IgG4-related sclerosing disease.
Nat. Rev. Gastroenterol. Hepatol. 7,
401–409.
Frontiers in Physiology | Gastrointestinal Sciences October 2012 | Volume 3 | Article 374 | 4
Kamisawa et al. Autoimmune pancreatitis
Kamisawa, T., Shimosegawa, T.,
Okazaki, K., Nishino, T., Watanabe,
H., Kanno, A., et al. (2009).
Standard steroid treatment for
autoimmune pancreatitis. Gut 58,
1504–1507.
Kawaguchi, K., Koike, M., Tsuruta,
K., Okamoto, A., Tsuruta,
K., and Fujita, N. (1991).
Lymphoplasmacytic sclerosing
pancreatitis with cholangitis: a
variant of primary sclerosing
cholangitis extensively involving
pancreas. Hum. Pathol. 22, 387–395.
Maruyama, M., Arakura, N., Ozaki,
Y., Watanabe, T., Ito, T., Yoneda,
S., et al. (2012). Risk factors for
pancreatic stone formation in
autoimmune pancreatitis over a
long-term course. J. Gastroenterol.
47, 553–560.
Notohara, K., Burgart, L. J., Yadav, D.,
Chari, S., and Smyrk, T. C. (2003).
Idiopathic chronic pancreatitis with
periductal lymphoplasmacytic infil-
tration. Clinicopathologic features
of 35 cases. Am. J. Surg. Pathol. 27,
1119–1127.
Park, D. H., Kim, M. H., and Chari,
S. T. (2009). Recent advances in
autoimmune pancreatitis. Gut 58,
1680–1689.
Sah, R. P., Chari, S. T., Pannala, R.,
Sugumar, A., Clain, J. E., Levy, M. J.,
et al. (2010). Differences in clinical
profile and relapse rate of type 1 ver-
sus type 2 autoimmune pancreatitis.
Gastroenterology 139, 140–148.
Sandanayake, N. S., Church, N. I.,
Chapman, M. H., Johnson, G. J.,
Dhar, D. K., Amin, Z., et al. (2009).
Presentation and management of
post-treatment relapse in autoim-
mune pancreatitis/immunoglobulin
G4-associated cholangitis.
Clin. Gastroenterol. Hepatol. 7,
1089–1096.
Shimosegawa, T., Chari, S. T.,
Frulloni, L., Kamisawa, T., Kawa,
S., Mino-Kenudson, M., et al.
(2011). International consensus
diagnostic criteria for autoim-
mune pancreatitis: guidelines
of the International Association
of Pancreatology. Pancreas 40,
352–358.
Takuma, K., Kamisawa, T., Tabata, T.,
Inaba, Y., Egawa, N., and Igarashi, Y.
(2011). Short-term and long-term
outcomes of autoimmune pancre-
atitis. Eur. J. Gastroenterol. Hepatol.
23, 146–152.
Yoshida, K., Toki, F., Takeuchi, T.,
Watanabe, S., Shiratori, K., and
Hayashi, N. (1995). Chronic
pancreatitis caused by an autoim-
mune abnormality. Proposal
of the concept of autoimmune
pancreatitis. Dig. Dis. Sci. 40,
1561–1568.
Zamboni, G., Luttges, J., Capelli, P.,
Frulloni, L., Cavallini, G., Pederzoli,
P., et al. (2004). Histopathological
features of diagnostic and clin-
ical relevance in autoimmune
pancreatitis: a study on 53 resec-
tion specimens and 9 biopsy
specimens. Virch. Arch. 445,
552–563.
Conflict of Interest Statement: The
authors declare that the research
was conducted in the absence of any
commercial or financial relationships
that could be construed as a potential
conflict of interest.
Received: 11 July 2012; accepted: 30
August 2012; published online: 02
October 2012.
Citation: Kamisawa T, Tabata T, Hara
S, Kuruma S, Chiba K, Kanno A,
Masamune A and Shimosegawa T
(2012) Recent advances in autoimmune
pancreatitis. Front. Physio. 3:374. doi:
10.3389/fphys.2012.00374
This article was submitted to Frontiers in
Gastrointestinal Sciences, a specialty of
Frontiers in Physiology.
Copyright © 2012 Kamisawa, Tabata,
Hara, Kuruma, Chiba, Kanno,
Masamune and Shimosegawa. This
is an open-access article distributed
under the terms of the Creative
Commons Attribution License, which
permits use, distribution and repro-
duction in other forums, provided
the original authors and source are
credited and subject to any copyright
notices concerning any third-party
graphics etc.
www.frontiersin.org October 2012 | Volume 3 | Article 374 | 5
